Irritable Bowel Syndrome Treatment Market Industry Will Grow Steadily with Leading Players Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc.,

Growing prevalence of irritable bowel syndrome associated with lifestyle factors, stress, and increasing number of options for the treatment are expected to be the major factors driving the growth of the global irritable bowel syndrome treatment market over the forecast period.

Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for symptom specific irritable bowel syndrome. Allergan plc received the U.S. Food & Drug Administration (FDA) approval for Viberzi (eluxadoline) for the treatment of IBS in adult men and women in 2015. Also, the company received approval of Health Canada for IBS-D in 2017. Valeant Pharmaceuticals International, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan for the treatment of IBS-D in 2015.

Download PDF Brochure of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/506

The major players are also expanding the product portfolio and their IBS therapies through mergers and acquisitions. Valeant Pharmaceuticals International, Inc. acquired Salix Pharmaceuticals, Inc. in 2015 along with the latter’s popular brand Xifaxan. The manufacturers are spreading the awareness about IBS through direct-to-consumer campaign advertisements for IBS drugs. For instance, Allergan and Ironwood Pharmaceuticals launched the first DTC campaign for Viberzi in 2015.

Furthermore, Sucampo Pharmaceuticals, Inc.’s pipeline products include lubiprostone for pediatric functional constipation (6 years – 17 years) in phase two and lubiprostone alternate formulation for pediatric constipation (6 months – 6 years). Also, Ardelyx, Inc. reported successful phase 3 T3MPO trial of Tenapanor in patients with irritable bowel syndrome with constipation.

Astellas Pharma, Inc. is conducting clinical trials for ASP7147, in the treatment of IBS. Norgine B.V. is having Plenvu, as osmotic laxative in clinical trials and the company entered into an agreement with Noventure to commercialize Gelsectan in Spain, Portugal and Andorra in 2017. Synthetic Biologics, Inc. is developing SYN-010 (modified-release reformulation of lovastatin lactone) as a therapy in irritable bowel syndrome with constipation.

Furthermore, major growth drivers for the irritable bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. According to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients suffering from gastrointestinal pain. The large population of stress and anxiety disorder patients are expected to fuel the growth of the global irritable bowel syndrome treatment market.

Request For Customization Of This Business Research Report:
https://www.coherentmarketinsights.com/insight/request-customization/506

Detailed Segmentation:

Global Irritable Bowel Syndrome Treatment Market, By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:
IBS-Constipation
IBS-Diarrhea
Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Global Irritable Bowel Syndrome Treatment Market, By Geography:
North America
By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
By Medical Condition:
IBS-Constipation
IBS-Diarrhea
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country:
U.S.
Canada

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.